TRIPLE-NEGATIVE BREAST CANCER: A REVIEW OF EVOLVING STRATEGIES

Fathima Manaal; Sanjana Bukka; Chaitanya Kallu; Narayana Reddy Gari Manasa Reddy; Narender Boggula

doi:10.47957/ijpda.v14i1.694

Authors

Manaal Fathima Omega College of Pharmacy, Edulabad, Ghatkesar, Hyderabad, Telangana, India.
Bukka Sanjana Omega College of Pharmacy, Edulabad, Ghatkesar, Hyderabad, Telangana, India.
Chaitanya Kallu Boonshoft School of Medicine, Wright State University, Dayton, Ohio, USA.
Narayana Reddy Gari Manasa Reddy Boonshoft School of Medicine, Wright State University, Dayton, Ohio, USA.
Narender Boggula Omega College of Pharmacy, Edulabad, Ghatkesar, Hyderabad, Telangana, India.

DOI:

https://doi.org/10.47957/ijpda.v14i1.694

Keywords:

Triple-negative breast cancer, human epidermal growth factor receptor 2, Small interfering RNA, cytokeratin pairs, tumour immune microenvironment

Abstract

Triple-negative breast cancer (TNBC) is a heterogeneous and aggressive group of tumors that are defined by the absence of estrogen and progesterone receptors and lack of ERBB2 (formerly HER2 or HER2/neu) overexpression. TNBC accounts for 8%–13% of breast cancers. In addition, it accounts for a higher proportion of breast cancers in younger women compared with those in older women, and it disproportionately affects non-Hispanic Black women.The survival rate for TNBCis generally worse than other breast cancer subtypes. TNBC treatment has made significant advances, but certain limitations remain. Triple negative breast cancer has a negative expression of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptors (HER2). The survival rate for TNBCis generally worse than other breast cancer subtypes.Early TNBC outcomes have improved due to the intensification of therapies, including improvements in polychemotherapy and the addition of immunotherapy. Future efforts are needed to identify targetable aberrations for specific drug therapy, prevent immune evasion, and increase social-economic support. The non-availability of specific treatment options for TNBC is usually managedbyconventional therapy, which often leads to relapse.The focus of this review is to provide up-to-date information related to pathophysiology, prognosis, treatment, challenges, and future perspectives. The data presented in this paper may be helpful for researchers working in the field to obtain general and information to advance the understanding of TNBC and provide suitable disease management in the future.

Downloads

Download data is not yet available.

References

Khongorzul, P.; Ling, C.J.; Khan, F.U.; Ihsan, A.U.; Zhang, J. Antibody-Drug Conjugates: A Comprehensive Review. Mol. Cancer Res. MCR. 2020; 18: 3–19.

Jusu, S.M.; Obayemi, J.D.; Salifu, A.A.; Nwazojie, C.C.; Uzonwanne, V.; Odusanya, O.S.; Soboyejo, W.O. Drug-Encapsulated Blend of PLGA-PEG Microspheres: In Vitro and in Vivo Study of the Effects of Localized/Targeted Drug Delivery on the Treatment of Triple-Negative Breast Cancer. Sci. Rep. 2020;10: 14188.

Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 2021; 71: 209–49.

Schick, J.; Ritchie, R.P.; Restini, C. Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. Breast Cancer Basic Clin. Res.2021; 15: 1178223421995854.

Palomeras, S.; Ruiz-Martínez, S.; Puig, T. Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance. Mol. J. Synth. Chem. Nat. Prod. Chem.2018; 23: 2193.

Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, Crosetto N, Foukakis T, Navin NE. Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. Cell. 2018;173(4):879-893.e13.

Zhang J, Zhang Y, Tang S, Liang H, Chen D, Jiang L, He Q, Huang Y, Wang X, Deng K, Jiang S, Zhou J, Xu J, Chen X, Liang W, He J. Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years. Ann Transl Med. 2017;5(24):481.

Vagia E, Mahalingam D, Cristofanilli M. The Landscape of Targeted Therapies in TNBC. Cancers. 2020; 12(4):916.

Goel V, Gosselin NH, Jomphe C, Zhang X, Marier JF, Robbie GJ. Population Pharmacokinetic-Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration. Nucleic Acid Ther. 2020;30(3):143-52.

Pi F, Binzel DW, Lee TJ, Li Z, Sun M, Rychahou P, Li H, Haque F, Wang S, Croce CM, Guo B, Evers BM, Guo P. Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression. Nat Nanotechnol. 2018;13(1):82-9.

Zhang Y, Zhang Y, Guo Q, Guo Z, Chen X, Liu L, Li C, Chen Q, He X, Lu Y, Sun T, Huang Y, Jiang C. Trained Macrophage Bioreactor for Penetrating Delivery of Fused Antitumor Protein. ACS Appl Mater Interfaces. 2019;11(26):23018-25.

Wang P, Zhang L, Zheng W, Cong L, Guo Z, Xie Y, Wang L, Tang R, Feng Q, Hamada Y, Gonda K, Hu Z, Wu X, Jiang X. Thermo-triggered Release of CRISPR-Cas9 System by Lipid-Encapsulated Gold Nanoparticles for Tumor Therapy. Angew Chem Int Ed Engl. 2018;57(6):1491-6.

Song Q, Yin Y, Shang L, Wu T, Zhang D, Kong M, Zhao Y, He Y, Tan S, Guo Y, Zhang Z. Tumor Microenvironment Responsive Nanogel for the Combinatorial Antitumor Effect of Chemotherapy and Immunotherapy. Nano Lett. 2017;17(10):6366-75.

Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, Rajeev KG, Nakayama T, Charrise K, Ndungo EM, Zimmermann T, Koteliansky V, Manoharan M, Stoffel M. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. NatBiotechnol. 2007;25(10):1149-57.

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52.

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-74.

Folsom AR, Pankow JS, Peacock JM, Bielinski SJ, Heiss G, Boerwinkle E. Variation in TCF7L2 and increased risk of colon cancer: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 2008;31(5):905-9.

A precarious milestone for quantum computing. Nature. 2019;574(7779):453-4.

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429-34.

Kulkarni JA, Witzigmann D, Thomson SB, Chen S, Leavitt BR, Cullis PR, van der Meel R. The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 2021;16(6):630-43.

Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129-38.

Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51-72.

Reis-Filho, J., Smith, I., Foulkes, W. Triple-Negative Breast Cancer. New England Journal of Medicine. 2014; 363(20): 1938–48.

Bianchini, G., Balko, J., Mayer, I. et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016; 13: 674–90.

Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.

Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395-9.

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-67.

Vasan, N., Baselga, J. Hyman, D.M. A view on drug resistance in cancer. Nature. 2019; 575: 299–309.

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541-50.

Roy, S., Zhuang, Y. Paradoxical role of Id proteins in regulating tumorigenic potential of lymphoid cells. Front. Med. 2018; 12: 374–86.

Wagner TH, Murray C, Goldberg J, Adler JM, Abrams J. Costs and benefits of the national cancer institute central institutional review board. J Clin Oncol. 2010;28(4):662-6.

TRIPLE-NEGATIVE BREAST CANCER: A REVIEW OF EVOLVING STRATEGIES

Authors

DOI:

Keywords:

Abstract

Downloads

References

Published

How to Cite

Issue

Section

Information